I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma

BACKGROUND: I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (~ 185 MBq, 10 mg). Seven of these patients undergoing sorafenib/immunotherapy w...

Descripción completa

Detalles Bibliográficos
Autores principales: Carrasquillo, Jorge A., O’Donoghue, Joseph A., Beylergil, Volkan, Ruan, Shutian, Pandit-Taskar, Neeta, Larson, Steven M., Smith-Jones, Peter M., Lyashchenko, Serge K., Ohishi, Norihisa, Ohtomo, Toshihiko, Abou-Alfa, Ghassan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838028/
https://www.ncbi.nlm.nih.gov/pubmed/29508107
http://dx.doi.org/10.1186/s13550-018-0374-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838028/
https://www.ncbi.nlm.nih.gov/pubmed/29508107
http://dx.doi.org/10.1186/s13550-018-0374-8

Ejemplares similares